Booming WuXi eyes $1.5B IPO for biologics unit: report

WuXi CEO Ge Li

Just months after taking the company private in a $3.3 billion deal, WuXi CEO Ge Li has begun setting the stage to spin out its rocketing biologics unit in an IPO that would value the business at $1.5 billion, according to a report from Bloomberg.

Based in Shanghai with facilities in the U.S., WuXi has achieved remarkably fast growth, emerging as the biggest contract research organization in China with extensive R&D and manufacturing ties throughout the world. In just the last few months the company has:

• Blueprinted a $120 million, 250,000-square-foot biologics discovery hub in Shanghai, with plans to bring together some 800 scientists.

• Struck a deal to jointly produce biologics with AstraZeneca ($AZN), which has partnered with WuXi on the development and commercialization of MEDI5117. AstraZeneca also has an option to buy a manufacturing facility from WuXi for $100 million.

• Added $290 million to its venture fund as it takes a stake in a growing group of U.S. biotechs that now includes Juno ($JUNO), Agios ($AGIO) and Twist Biosciences.

Bank of America and Morgan Stanley have been brought in to handle a Hong Kong share sale, Bloomberg reports, citing sources close to the deal. WuXi pulled out of the New York Stock Exchange on December 10.

Ge Li and his top executive crew have earned a reputation for fast-paced dealmaking that's unprecedented in China's growing biopharma business. And clearly they're still in the early stages of wheeling and dealing with some of the biggest, and smallest, players in the global industry.

- here's the story
- get FierceCRO's take

Special Report: The 25 most influential people in biopharma in 2015 - Ge Li - WuXi PharmaTech

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.